Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Hyperlipidemia Is Secondary to Proteinuria and Is Completely Normalized by Angiotensin-Converting Enzyme Inhibition in Hypertensive Fawn-Hooded Rats

View through CrossRef
Two substrains of the fawn-hooded (FH) rat have been developed, one of which develops progressive hypertension and proteinuria, the FHH, and one which shows little increase in blood pressure and no renal damage, the FHL. Other hypertensive rodent models show primary metabolic disturbances before the development of renal damage, notably hypertriglyceridemia, which may also contribute to progression of renal disease. In this study we evaluated whether hyperlipidemia is a primary disturbance in FHH, or only occurs secondary to proteinuria. Lipid levels were determined before and after development of proteinuria, and compared to those found in age-matched FHL. We also determined whether reducing proteinuria with lisinopril would normalize lipid levels in aging FHH. At 4 weeks of age, proteinuria was very low (2-3 mg/day) in both FHH and FHL. While proteinuria increased steadily in aging FHH, reaching 350 ± 62 mg/day at 40 weeks, much less increase was observed in FHL over the same period (32 ± 5 mg/day at 40 weeks). Blood pressure was markedly higher in adult FHH than in FHL (158 ± 2 vs. 129 ± 2 mm Hg, p < 0.01). In 4-week-old FHL and FHH, plasma cholesterol levels were similar. Subsequently, cholesterol increased in FHH, reaching 3.4 ± 0.9 mmol/l at 40 weeks, whereas cholesterol was barely affected by aging in FHL (2.1 ± 0.2 mmol/l at 40 weeks). At 4 weeks, triglyceride levels were lowest in FHH. Subsequently, triglycerides increased in FHH, reaching 3.5 ± 1.5 mmol/l at 40 weeks, as compared to 1.3 ± 0.2 mmol/l in FHL. Besides a transient increase in triglyerides in lisinopril-treated FHH at 11 weeks, increments in blood pressure, proteinuria, cholesterol, triglycerides and apolipoproteins A-I, B and E aging FHH were effectively prevented by lisinopril. These data strongly suggest that there is no primary difference in lipid metabolism between FHH and FHL and that changes in plasma lipids in FHH as compared to FHL are all secondary to proteinuria.
Title: Hyperlipidemia Is Secondary to Proteinuria and Is Completely Normalized by Angiotensin-Converting Enzyme Inhibition in Hypertensive Fawn-Hooded Rats
Description:
Two substrains of the fawn-hooded (FH) rat have been developed, one of which develops progressive hypertension and proteinuria, the FHH, and one which shows little increase in blood pressure and no renal damage, the FHL.
Other hypertensive rodent models show primary metabolic disturbances before the development of renal damage, notably hypertriglyceridemia, which may also contribute to progression of renal disease.
In this study we evaluated whether hyperlipidemia is a primary disturbance in FHH, or only occurs secondary to proteinuria.
Lipid levels were determined before and after development of proteinuria, and compared to those found in age-matched FHL.
We also determined whether reducing proteinuria with lisinopril would normalize lipid levels in aging FHH.
At 4 weeks of age, proteinuria was very low (2-3 mg/day) in both FHH and FHL.
While proteinuria increased steadily in aging FHH, reaching 350 ± 62 mg/day at 40 weeks, much less increase was observed in FHL over the same period (32 ± 5 mg/day at 40 weeks).
Blood pressure was markedly higher in adult FHH than in FHL (158 ± 2 vs.
129 ± 2 mm Hg, p < 0.
01).
In 4-week-old FHL and FHH, plasma cholesterol levels were similar.
Subsequently, cholesterol increased in FHH, reaching 3.
4 ± 0.
9 mmol/l at 40 weeks, whereas cholesterol was barely affected by aging in FHL (2.
1 ± 0.
2 mmol/l at 40 weeks).
At 4 weeks, triglyceride levels were lowest in FHH.
Subsequently, triglycerides increased in FHH, reaching 3.
5 ± 1.
5 mmol/l at 40 weeks, as compared to 1.
3 ± 0.
2 mmol/l in FHL.
Besides a transient increase in triglyerides in lisinopril-treated FHH at 11 weeks, increments in blood pressure, proteinuria, cholesterol, triglycerides and apolipoproteins A-I, B and E aging FHH were effectively prevented by lisinopril.
These data strongly suggest that there is no primary difference in lipid metabolism between FHH and FHL and that changes in plasma lipids in FHH as compared to FHL are all secondary to proteinuria.

Related Results

Molecular and Physiological Aspects of Angiotensin I Converting Enzyme
Molecular and Physiological Aspects of Angiotensin I Converting Enzyme
AbstractThe sections in this article are:DistributionSomatic Angiotensin‐Converting EnzymeGerminal Angiotensin‐Converting EnzymeCatalytic PropertiesAngiotensin‐Converting Enzyme Is...
Body Mass Index and the Risk of Persistent Proteinuria in Middle-Aged Men: The Kansai Healthcare Study
Body Mass Index and the Risk of Persistent Proteinuria in Middle-Aged Men: The Kansai Healthcare Study
<b><i>Introduction:</i></b> Proteinuria is a risk factor for end-stage renal failure. However, it is not known whether body mass index (BMI) is prospectivel...
HOW TO INTERPRET URINARY PROTEINURIA AS A MARKER OF HYPERTENSIVE NEPHROPATHY?
HOW TO INTERPRET URINARY PROTEINURIA AS A MARKER OF HYPERTENSIVE NEPHROPATHY?
Objective: Proteinuria may be the first sign of underlying nephropathy. It is pathological when the value is higher than 0.15 g/24h. The gold standard of qu...
Development of angiotensin (1‐7) as an agent to accelerate dermal repair
Development of angiotensin (1‐7) as an agent to accelerate dermal repair
Angiotensin II has been shown to be a potent agent in the acceleration of wound repair. Angiotensin (1‐7), a fragment of angiotensin II that is not hypertensive, was found to be co...
Abstract 125: Modified Angiotensin II Has Lower Vasoconstrictive Effect Than Angiotensin II
Abstract 125: Modified Angiotensin II Has Lower Vasoconstrictive Effect Than Angiotensin II
Introduction: The renin-angiotensin-aldosterone system (RAAS) is involved in the regulation of the blood pressure, water- and electrolyte balance. Pathophysiologically,...
MO093CLARIFICATION OF BIOSYNTHESIS OF ANGIOPROTECTIN
MO093CLARIFICATION OF BIOSYNTHESIS OF ANGIOPROTECTIN
Abstract Background and Aims The renin-angiotensin-aldosterone system (RAAS) is involved in the regulation of the blood pressure...

Back to Top